Free Trial
NASDAQ:SHPH

Shuttle Pharmaceuticals Q1 2026 Earnings Report

Shuttle Pharmaceuticals logo
$0.49 +0.04 (+8.07%)
Closing price 04:00 PM Eastern
Extended Trading
$0.47 -0.02 (-4.29%)
As of 05:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Shuttle Pharmaceuticals EPS Results

Actual EPS
-$0.43
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Shuttle Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Shuttle Pharmaceuticals Announcement Details

Quarter
Q1 2026
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Shuttle Pharmaceuticals Earnings Headlines

Shuttle Pharmaceuticals Holdings Inc SHPH
Shuttle Pharmaceuticals Holdings, Inc.
How to claim a stake in SpaceX before the June 12 IPO
SpaceX is expected to go public on June 12 - and for the first time, everyday investors may have a way in before the IPO. Jeff Brown, who identified Bitcoin, Tesla, and Nvidia before gains as high as 52,400%, 2,150%, and 32,000% respectively, is sharing the details on how to claim a stake in Elon Musk's company before it hits public markets.tc pixel
See More Shuttle Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Shuttle Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Shuttle Pharmaceuticals and other key companies, straight to your email.

About Shuttle Pharmaceuticals

Shuttle Pharmaceuticals (NASDAQ:SHPH), a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers . The company is based in Gaithersburg, Maryland.

View Shuttle Pharmaceuticals Profile